Blood test could predict nerve disease onset in At-Risk families

This study aims to see if a protein in the blood, called neurofilament light chain (NfL), can be a useful marker for a rare nerve disease called hATTR amyloidosis. It will measure NfL levels in 500 people who carry the gene for the disease but have no symptoms, and in those who already have symptoms. The goal is to learn if this blood test can help detect when the disease starts, monitor its progression, and see how patients respond to treatment changes.